Mahla E, Raggam R, Toller W
Elisabeth Mahla, M.D., Department of Anesthesiology and Intensive Care, Medicine, Research Unit for Perioperative Platelet, Function, Medical University of Graz, Auenbruggerplatz 29, 8036 Graz, Austria, Tel. +43/316/38 51 30 27, Fax +43/316/38 51 32 67, E-mail:
Hamostaseologie. 2014;34(1):40-5. doi: 10.5482/HAMO-13-06-0032. Epub 2013 Sep 27.
In patients pretreated with P2Y12 receptor inhibitors who need to undergo non-emergent cardiac or major non-cardiac surgery, current guidelines of the European Society of Cardiology recommend postponing surgery for at least five days after last intake of clopidogrel or ticagrelor, and for seven days after last intake of prasugrel, unless there is high risk of ischemic events. However, a fixed five to seven days preoperative waiting period may be challenged, in the presence of inter-individual variability in on-treatment platelet reactivity. Therefore, Society of Thoracic Surgeons guidelines suggest to base decisions about a surgical delay on platelet function although both, the optimal platelet function assay and a bleeding cutoff have not yet been defined by large scale multicenter trials. This review aims to provide an overview on current knowledge of P2Y12 receptor induced platelet inhibition and surgery related bleeding and the potential role of platelet function analysis to time surgery.
对于已经接受P2Y12受体抑制剂治疗且需要进行非急诊心脏手术或重大非心脏手术的患者,欧洲心脏病学会的现行指南建议,在最后一次服用氯吡格雷或替格瑞洛后至少推迟五天进行手术,在最后一次服用普拉格雷后七天进行手术,除非存在缺血事件的高风险。然而,考虑到治疗期间血小板反应性存在个体差异,固定的术前五到七天等待期可能受到挑战。因此,胸外科医师协会的指南建议根据血小板功能来决定是否推迟手术,尽管大规模多中心试验尚未确定最佳的血小板功能检测方法和出血阈值。本综述旨在概述目前关于P2Y12受体诱导的血小板抑制和手术相关出血的知识,以及血小板功能分析在确定手术时机方面的潜在作用。